These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 31767542)

  • 21. Functional analysis of the 1p34.3 risk locus implicates GNL2 in high-grade serous ovarian cancer.
    Nakamura K; Reid BM; Chen A; Chen Z; Goode EL; Permuth JB; Teer JK; Tyrer J; Yu X; Kanetsky PA; Pharoah PD; Gayther SA; Sellers TA; Lawrenson K; Karreth FA
    Am J Hum Genet; 2022 Jan; 109(1):116-135. PubMed ID: 34965383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting estrogen metabolism in high-grade serous ovarian cancer shows promise to overcome platinum resistance.
    Marolt N; Pavlič R; Kreft T; Gjogorska M; Rižner TL
    Biomed Pharmacother; 2024 Aug; 177():117069. PubMed ID: 38968802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.
    Tassi RA; Gambino A; Ardighieri L; Bignotti E; Todeschini P; Romani C; Zanotti L; Bugatti M; Borella F; Katsaros D; Tognon G; Sartori E; Odicino F; Romualdi C; Ravaggi A
    Br J Cancer; 2019 Oct; 121(7):584-592. PubMed ID: 31434988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrative prognostic subtype discovery in high-grade serous ovarian cancer.
    Xie H; Xu H; Hou Y; Cai Y; Rong Z; Song W; Wang W; Li K
    J Cell Biochem; 2019 Nov; 120(11):18659-18666. PubMed ID: 31347734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.
    Dai W; Zeller C; Masrour N; Siddiqui N; Paul J; Brown R
    Clin Cancer Res; 2013 Oct; 19(20):5788-5797. PubMed ID: 23965899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.
    Tudrej P; Olbryt M; Zembala-Nożyńska E; Kujawa KA; Cortez AJ; Fiszer-Kierzkowska A; Pigłowski W; Nikiel B; Głowala-Kosińska M; Bartkowska-Chrobok A; Smagur A; Fidyk W; Lisowska KM
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
    Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.
    Luo LY; Kim E; Cheung HW; Weir BA; Dunn GP; Shen RR; Hahn WC
    Mol Cancer Res; 2015 Mar; 13(3):502-9. PubMed ID: 25368431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
    Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
    Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.
    Leonard B; Starrett GJ; Maurer MJ; Oberg AL; Van Bockstal M; Van Dorpe J; De Wever O; Helleman J; Sieuwerts AM; Berns EM; Martens JW; Anderson BD; Brown WL; Kalli KR; Kaufmann SH; Harris RS
    Clin Cancer Res; 2016 Sep; 22(18):4746-55. PubMed ID: 27016308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
    Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
    Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
    Tucker DW; Getchell CR; McCarthy ET; Ohman AW; Sasamoto N; Xu S; Ko JY; Gupta M; Shafrir A; Medina JE; Lee JJ; MacDonald LA; Malik A; Hasselblatt KT; Li W; Zhang H; Kaplan SJ; Murphy GF; Hirsch MS; Liu JF; Matulonis UA; Terry KL; Lian CG; Dinulescu DM
    Clin Cancer Res; 2018 Mar; 24(6):1389-1401. PubMed ID: 29263182
    [No Abstract]   [Full Text] [Related]  

  • 33. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-grade Serous Ovarian Carcinoma.
    Tangri A; Lighty K; Loganathan J; Mesmar F; Podicheti R; Zhang C; Iwanicki M; Drapkin R; Nakshatri H; Mitra S
    Mol Cancer Res; 2021 Jul; 19(7):1168-1181. PubMed ID: 33753553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated bioinformatic analysis identifies UBE2Q1 as a potential prognostic marker for high grade serous ovarian cancer.
    Topno R; Singh I; Kumar M; Agarwal P
    BMC Cancer; 2021 Mar; 21(1):220. PubMed ID: 33663405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
    Hillman RT; Chisholm GB; Lu KH; Futreal PA
    J Natl Cancer Inst; 2018 Mar; 110(3):265-72. PubMed ID: 29584920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated weighted gene co-expression network analysis reveals biomarkers associated with prognosis of high-grade serous ovarian cancer.
    Wang B; Chao S; Guo B
    J Clin Lab Anal; 2022 Feb; 36(2):e24165. PubMed ID: 34997982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
    Petersen S; Wilson AJ; Hirst J; Roby KF; Fadare O; Crispens MA; Beeghly-Fadiel A; Khabele D
    Gynecol Oncol; 2020 May; 157(2):405-410. PubMed ID: 32044108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling.
    Khella CA; Franciosa L; Rodirguez-Rodriguez L; Rajkarnikar R; Mythreye K; Gatza ML
    Mol Cancer Res; 2023 Oct; 21(10):1037-1049. PubMed ID: 37342066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of PRC1 indicates a poor prognosis in ovarian cancer.
    Bu H; Li Y; Jin C; Yu H; Wang X; Chen J; Wang Y; Ma Y; Zhang Y; Kong B
    Int J Oncol; 2020 Mar; 56(3):685-696. PubMed ID: 31922238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.